Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

CIRESI, Alessandro
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.637
EU - Europa 5.049
AS - Asia 4.358
SA - Sud America 702
AF - Africa 140
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 5
Totale 19.901
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.505
SG - Singapore 1.571
IT - Italia 1.502
CN - Cina 1.234
RU - Federazione Russa 1.063
FI - Finlandia 540
BR - Brasile 528
VN - Vietnam 382
DE - Germania 375
HK - Hong Kong 375
PL - Polonia 261
FR - Francia 258
UA - Ucraina 250
IE - Irlanda 249
GB - Regno Unito 211
JP - Giappone 148
KR - Corea 133
SE - Svezia 97
IN - India 82
TR - Turchia 80
AR - Argentina 68
BD - Bangladesh 59
CA - Canada 51
NL - Olanda 45
MX - Messico 43
CI - Costa d'Avorio 40
IQ - Iraq 40
RO - Romania 35
AT - Austria 32
BE - Belgio 32
CL - Cile 32
PK - Pakistan 30
ES - Italia 28
ZA - Sudafrica 27
NP - Nepal 23
UZ - Uzbekistan 21
AE - Emirati Arabi Uniti 19
SA - Arabia Saudita 19
MA - Marocco 18
MY - Malesia 18
EC - Ecuador 17
ID - Indonesia 17
KE - Kenya 15
PH - Filippine 15
PY - Paraguay 14
CO - Colombia 13
JO - Giordania 13
CZ - Repubblica Ceca 12
IR - Iran 12
TN - Tunisia 12
UY - Uruguay 12
CH - Svizzera 11
VE - Venezuela 11
AL - Albania 9
LB - Libano 9
AU - Australia 8
CR - Costa Rica 8
DZ - Algeria 8
EG - Egitto 8
BG - Bulgaria 7
GR - Grecia 7
IL - Israele 7
SY - Repubblica araba siriana 7
TH - Thailandia 7
TW - Taiwan 7
JM - Giamaica 6
PE - Perù 6
DK - Danimarca 5
HN - Honduras 5
LT - Lituania 5
AM - Armenia 4
AZ - Azerbaigian 4
BH - Bahrain 4
DO - Repubblica Dominicana 4
KZ - Kazakistan 4
MK - Macedonia 4
A2 - ???statistics.table.value.countryCode.A2??? 3
OM - Oman 3
PA - Panama 3
SN - Senegal 3
SV - El Salvador 3
AO - Angola 2
BS - Bahamas 2
BY - Bielorussia 2
CY - Cipro 2
EU - Europa 2
GE - Georgia 2
GT - Guatemala 2
KG - Kirghizistan 2
MD - Moldavia 2
NI - Nicaragua 2
NZ - Nuova Zelanda 2
RS - Serbia 2
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BW - Botswana 1
ET - Etiopia 1
GD - Grenada 1
Totale 19.887
Salva come PNG Salva come JPEG
Città #
Fairfield 1.162
Ashburn 1.083
Singapore 981
Woodbridge 593
Wilmington 529
Houston 506
Seattle 463
Chandler 454
San Jose 449
Cambridge 380
Hong Kong 364
Ann Arbor 334
Council Bluffs 318
Dublin 249
Zgierz 227
Medford 197
Moscow 195
Beijing 186
Des Moines 169
Palermo 154
Tokyo 146
Jacksonville 141
Nanjing 132
Princeton 125
Helsinki 121
Ho Chi Minh City 112
Hanoi 110
Lauterbourg 110
Los Angeles 107
New York 105
Santa Clara 102
Frankfurt am Main 100
Dallas 96
Dearborn 84
Altamura 80
Boardman 78
San Diego 69
Milan 62
Changsha 58
Chicago 57
Lawrence 55
Jinan 54
Nanchang 51
Tulsa 50
Rome 49
Tianjin 46
Hebei 45
São Paulo 43
Atlanta 42
Phoenix 42
Izmir 41
Jiaxing 41
Abidjan 40
The Dalles 38
Seongnam 37
Buffalo 36
Shenyang 36
London 32
Brussels 30
Ludwigshafen am Rhein 30
Ningbo 30
Falls Church 28
Zhengzhou 27
Orem 26
Redwood City 25
Santiago 25
Da Nang 24
Guangzhou 24
Nuremberg 23
Saint Petersburg 22
Hefei 21
Rio de Janeiro 20
Munich 19
Baghdad 17
Kumar 17
Amsterdam 16
Hangzhou 16
Johannesburg 16
Denver 15
Shanghai 15
Taizhou 15
Basingstoke 14
Bucheon-si 14
Frankfurt 14
Montreal 14
Tashkent 14
Vienna 14
Amman 13
Auburn Hills 13
Columbus 13
San Paolo di Civitate 13
Toronto 13
Chennai 12
Guarulhos 12
Nairobi 12
Naples 12
Taiyuan 12
Bari 11
Brooklyn 11
City of London 11
Totale 12.509
Salva come PNG Salva come JPEG
Nome #
The Daily Consumption of Cola Can Determine Hypocalcemia: A Case Report of Postsurgical Hypoparathyroidism-Related Hypocalcemia Refractory to Supplemental Therapy with High Doses of Oral Calcium 397
Valutazione dell’insulino-sensibilità tramite clamp euglicemico iperinsulinemico in bambini in terapia sostitutiva con GH. 351
Predictors of microvascular complications in type 1 diabetic patients at onset: The role of metabolic memory 320
Alteration of the growth hormone axis, visceral fat dysfunction, and early cardiometabolic risk in adults: the role of the visceral adiposity index 266
Clinical and metabolic effects of first-line treatment with somatostatin analogues or surgery in acromegaly: a retrospective and comparative study 265
Metabolic parameters and adipokine profile during GH replacement therapy in children with GH deficiency 263
Identification of Novel Wsf1 Mutations in a Sicilian Child with Wolfram Syndrome 263
Insulin resistance and hyperandrogenism drive steatosis and fibrosis risk in young females with PCOS 255
Hepatic steatosis index in acromegaly: Correlation with insulin resistance regardless of the disease control 249
Commento a "Resistin, visfatin, leptin and omentin are differently related to hormonal and metabolic parameters in growth hormone-deficient children " 239
L’insulino-resistenza è il principale fattore indipendente correlato con l’aumentato rischio metabolico nelle donne affette da PCOS 236
Diabete e complicanze materno-fetali in gravidanza: confronto tra pazienti con diabete tipo 1 e tipo 2 pregravidico. 231
Cornea in acromegalic patients as a possible target of growth hormone action. 230
OCT is not useful for detection of minimal diabetic retinopathy in type 1 diabetes. 228
Early Lung Function Abnormalities in Acromegaly. 228
Janus kinase (JAK) 2 V617F mutation as the cause of primary thrombocythemia in acromegaly with severe visceromegaly and divergence between growth hormone and insulin-like growth factor-1 concentrations during the follow-up: causal or casual association? 228
Comparison between euglycemic hyperinsulinemic clamp and surrogate indices of insulin sensitivity in children with growth hormone deficiency 227
GHD come predittore di sindrome metabolica 225
Visceral Adiposity Index Is Associated with Insulin Sensitivity and Adipocytokine Levels in Newly Diagnosed Acromegalic Patients. 221
The degree of urinary hypercortisolism is not correlated with the severity of cushing’s syndrome 220
Circulating Irisin Levels in Children with GH Deficiency before and after 1 Year of GH Treatment 219
Complete biochemical control and pituitary adenoma disappearance in a child with gigantism: efficacy of octreotide therapy 218
Clamp euglicemico iperinsulinemico e test al glucagone come utili strumenti di valutazione degli effetti metabolici della terapia sostitutiva con GH. 213
Correlation between adrenal function, growth hormone secretion, and insulin sensitivity in children with idiopathic growth hormone deficiency 210
Commento a "The impact of real practice inappropriateness and devices' inefficiency to variability in growth hormone consumption" 205
Dual-release hydrocortisone vs conventional glucocorticoids in adrenal insufficiency 205
Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels. 201
Il c-peptide come marker principale nella storia naturale del Diabete tipo 1: ruolo della funzione b-cellulare pancreatica nelle complicanze 200
Lacrimal glands herniation in patients with Graves’ Ophthalmopathy: an effective MRI-derived marker of disease activity 199
Visceral adiposity index is associated with insulin sensitivity and adipocytokine levels in newly diagnosed acromegalic patients. 196
The metabolic outcomes of growth hormone treatment in children are gender specific 195
Relative Hypoleptinemia in poor controlled patients with Type 1 Diabetes 190
The Metabolic Profile in Active Acromegaly is Gender-Specific. 190
Hyperinsulinism and polycystic ovary syndrome (PCOS): role of insulin clearance. 189
Liraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A Real-life 48-Month Retrospective Study. 189
Pasireotide versus pituitary surgery: a retrospective analysis of 12 months of treatment in patients with Cushing's disease 186
Improved insulin sensitivity and secretion in prediabetic patients with adrenal insufficiency on dual-release hydrocortisone treatment: a 36-month retrospective analysis 185
Difficoltà di identificazione della sindrome MEN2B ad esordio infantile: iter diagnostico. 184
Systolic flow peak of inferior thyroid arteries in Graves’disease: A predictive parameter for the ophalmopathy development. 183
Alterazioni del metabolismo glucidico determinate da eccesso di ormoni controregolatori: ruolo del GH 183
Growth hormone and hematopoiesis: A retrospective analysis on a large cohort of children with growth hormone deficiency 183
Insulin sensitivity and secretion and adipokine profile in patients with Cushing’s disease treated with pasireotide 183
Is diabetes in Cushing's syndrome only a consequence of hypercortisolism? 182
Corneal thickness in children with growth hormone deficiency: The effect of GH treatment. 182
The visceral adiposity index is associated with insulin sensitivity and IGF-I levels in adults with growth hormone deficiency 182
Resistin, visfatin, leptin and omentin are differently related to hormonal and metabolic parameters in growth hormone-deficient children 179
Rivalutazione delle caratteristiche cliniche e metaboliche di bambini con deficit isolato di ormone della crescita durante il trattamento con GH secondo la modifica alla nota 39 AIFA 179
Changes in lipid profile and adipokine levels in GH deficient children during GH replacement therapy. 176
Vitamin D across growth hormone (GH) disorders: From GH deficiency to GH excess 176
Utility of C-peptide for a reliable estimate of insulin secretion in children with growth hormone deficiency. 175
Lacrimal gland herniation in Graves ophthalmopathy: a simple and useful MRI biomarker of disease activity 175
Correlation between Severity of Growth Hormone Deficiency and Thyroid Metabolism and Effects of Long-Term Growth Hormone Treatment on Thyroid Function in Children with Idiopathic Growth Hormone Deficiency. 174
Studio randomizzato controllato, della durata di 2 anni, sugli effetti e la sicurezza di differenti dosaggi di r-hGH, titolati sulla base dei livelli di IGF1 in pazienti con bassa statura in trattamento: considerazioni terapeutiche e farmacoeconomiche 173
Adrenal incidentaloma: a new contributing factor in metabolic syndrome 171
No phenotypic differences for polycystic ovary syndrome (PCOS) between women with and without type 1 diabetes mellitus. 171
Alta prevalenza di Sindrome dell’ovaio policistico in donne diabetiche di tipo 1 in età fertile. 167
Alte dosi di cabergolina migliorano i parametri metabolici in pazienti affetti da prolattinoma. 166
GH-suppression test in acromegaly: comparison between OGTT and chocolate test 164
Alterazioni del metabolismo glucidico determinate da eccesso di ormoni contro regolatori. 164
Glycometabolic control in Acromegalic patients with Diabetes: a study of the effects of different treatments for GH excess and for hyperglycaemia. 163
Adrenal incidentaloma: a new contributing factor in metabolic syndrome? 163
Revaluation of the clinical and metabolic behavior of children with isolated growth hormone deficiency during GH treatment according to newly proposed note 39 of the Italian Medicines Agency (AIFA). 163
Higher cardiometabolic risk in idiopathic versus autoimmune type 1 diabetes: A retrospective analysis 163
Diabetes Secondary to Acromegaly: Physiopathology, Clinical Features and Effects of Treatment. 163
Leptina e adiponectina nella valutazione del compenso glicometabolico in corso di diabete mellito di tipo 1 normopeso. 162
Circulating adipokine levels in diabetic patients with Cushing disease on pasireotide treatment compared with patients with type 2 diabetes mellitus 161
The lacrimal gland herniation role in the Graves’ orbitopathy 161
No effect of GH/IGF-1 excess on adrenal glands in acromegalic patients 160
Buon compenso glicemico nei pazienti acromegalici affetti da diabete secondario. 160
Prevalence and clinical features of polycystic ovarian syndrome in adolescents with previous childhood growth hormone deficiency 158
Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report 157
Serum visfatin levels in acromegaly: Correlation with disease activity and metabolic alterations 156
Decreased regulatory CD4+CD25+ Treg cells in newly diagnosed type 1 diabetes 155
Erratum to: Liraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A Real-life 48-Month Retrospective Study (Diabetes Therapy, (2018), 9, 1, (363-371), 10.1007/s13300-017-0338-4) 155
Pasireotide treatment reduces cardiometabolic risk in Cushing’s disease patients: an Italian, multicenter study 152
Iter diagnostico "rapido" per un caso di MEN IIb in un giovane adolescente 151
Reduction in insulin sensitivity and inadequate β-cell capacity to counteract the increase in insulin resistance in children with idiopathic growth hormone deficiency during 12 months of growth hormone treatment 146
Comparison of clinical and metabolic effects of pasireotide and pituitary surgery in Cushing disease 146
Visceral Adipose function, insulin sensitivity and secretion in active acromegaly. 144
EFFECTS OF PASIREOTIDE TREATMENT ON CARDIOMETABOLIC RISK IN PATIENTS WITH CUSHING’S DISEASE : AN ITALIAN, MULTICENTER STUDY 144
Increased central corneal thickness in acromegalic patients. 139
Maggiore rischio cardiometabolico in pazienti di razza non caucasica affetti da diabete mellito di tipo 1 idiopatico rispetto alla forma autoimmune in pazienti caucasici. 139
The adipose visceral dysfunction plays an important role in diabetes in Cushing disease. 136
Clinical and metabolic impact of three-times-weekly versus daily growth hormone (GH) treatment in naïve GH-deficient children 132
Glucose metabolism in children with growth hormone deficiency 132
Improved cardiovascular and cardiometabolic risk in patients with type 1 diabetes and autoimmune polyglandular syndrome switched from glargine to degludec due to hypoglycaemic variability 131
Miglioramento clinico e metabolico in pazienti affetti da diabete mellito tipo 1 associato ad altre endocrinopatie (APS) dopo shift della terapia insulinica basale con glargine a degludec 130
La valutazione retinica mediante Tomografia a Coerenza Ottica (OCT) nel diabete mellito tipo 1. 129
Adrenal morphology and function in acromegalic patients in relation to disease activity. 129
IL CONSUMO DI BEVANDE RICCHE DI ACIDO ORTOFOSFORICO COME FATTORE DI RISCHIO PER LO SVILUPPO DI IPOCALCEMIA: IL CASO DI UNA DONNA CON IPOPARATIROIDISMO POST-CHIRURGICO 127
GH-treatment improves growth and reduces the severity of fibrosis and hypertansaminasemia in a prepubertal child with sclerosant cholangiopathy 125
Il c-peptide come marker principale nella storia naturale del Diabete di tipo 1: ruolo della funzione b-cellulare pancreatica nelle complicanze. 124
Effects of pasireotide treatment on coagulative profile: a prospective study in patients with Cushing’s disease 124
Janus kinase (JAK) 2 V617F mutation as the cause of primary thrombocythemia, severe visceromegaly and divergence between growth hormone and insulin-like growth factor-1 concentrations in acromegaly due to a therapeutically resistant pituitary GH-secreting macroadenoma 121
IPOVITAMINOSI D ED EFFETTI BENEFICI DELLA TERAPIA SOSTITUTIVA CON GH SUI LIVELLI DI VITAMINA D IN BAMBINI AFFETTI DA DEFICIT DI GH 121
High prevalence of hypovitaminosis D in Sicilian children affected by growth hormone deficiency and its improvement after 12 months of replacement treatment. 121
Increated central corneal thickness in acromegalic patients 114
Impact of obesity, insulin resistance and hyperandrogenism on steatosis and fibrosis risk in young females with PCOS 114
No effect of GH/IGF-1 excess on adrenal gland in Acromegalic patients. 113
More favorable metabolic impact of three-times-weekly versus daily growth hormone (GH) treatment in naïve GH-deficient children 112
Totale 18.200
Salva come PNG Salva come JPEG
Categoria #
all - tutte 65.746
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 65.746
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021302 0 0 0 0 0 0 0 0 0 0 124 178
2021/20221.382 51 250 49 62 70 70 41 80 143 190 81 295
2022/20231.537 183 229 24 160 172 250 132 103 163 13 78 30
2023/2024763 23 119 45 68 76 138 81 60 9 44 10 90
2024/20251.975 97 75 147 179 71 60 80 203 164 208 267 424
2025/20266.910 384 216 361 499 616 1.030 1.246 735 575 981 267 0
Totale 20.702